Amy J. Johnson

Michael R. Grever8
Amy S. Ruppert6
Leslie Andritsos6
David Jarjoura3
8Michael R. Grever
6Amy S. Ruppert
6Leslie Andritsos
3David Jarjoura
Learn More
  • Kristie A. Blum, Amy S. Ruppert, Jennifer A. Woyach, Jeffrey A. Jones, Leslie Andritsos, Joseph M. Flynn +7 others
  • 2011
Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In univariable analysis, female gender,(More)
BACKGROUND Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in patients with refractory chronic lymphocytic leukemia. This study aimed to evaluate pharmacogenetic(More)
  • David M. Lucas, Lapo Alinari, Derek A. West, Melanie E. Davis, Ryan B. Edwards, Amy J. Johnson +14 others
  • 2010
BACKGROUND While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in(More)
Dinaciclib (SCH727965) is a selective CDKi chosen for clinical development based upon a favorable therapeutic index in cancer xenograft models. We performed a phase I dose escalation study of dinaciclib in relapsed and refractory chronic lymphocytic leukemia (CLL) patients with intact organ function and WBC<200 × 10(9) /l. Five separate dose levels (5(More)
  • Daphne Guinn, Amy S. Ruppert, Kami Maddocks, Samantha Jaglowski, Amber Gordon, Thomas S. Lin +6 others
  • 2015
Chronic lymphocytic leukemia (CLL) is an incurable disease identified most commonly in elderly patients. Interphase cytogenetics, IGHV status and ZAP70 protein expression/ methylation have been used to risk-stratify patients relative to likelihood of disease progression or treatment assignment when CLL becomes symptomatic Reviewed in 1. microRNAs are short(More)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments. Here we describe a novel CLL cell line (OSU-CLL) generated by EBV transformation, which displays a(More)
  • Darlene M. Rozewski, Sarah E. M. Herman, William H. Towns, Emilia Mahoney, Matthew R. Stefanovski, Jungook D. Shin +7 others
  • 2012
Lenalidomide is a synthetic derivative of thalidomide exhibiting multiple immunomodulatory activities beneficial in the treatment of several hematological malignancies. Murine pharmacokinetic characterization necessary for translational and further preclinical investigations has not been published. Studies herein define mouse plasma pharmacokinetics and(More)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar to human diffuse large B-cell lymphoma (DLBCL). First, we(More)
Epigenetic or transcriptional silencing of important tumor suppressors has been described to contribute to cell survival and tumorigenesis in chronic lymphocytic leukemia (CLL). Using gene expression microarray analysis, we found that thousands of genes are repressed more than 2-fold in CLL compared to normal B cells; however therapeutic approaches to(More)